AbbVie, Regenxbio to Partner on Eye Therapy
September 13 2021 - 7:11AM
Dow Jones News
By Matt Grossman
AbbVie Inc. and Regenxbio Inc. will collaborate on bringing to
market a new drug for wet age-related macular degeneration, an eye
disease, the companies said Monday.
Regenxbio, based in Rockville, Md., has been developing the
drug, a one-time gene therapy called RGX-314. Under the terms of
the partnership, AbbVie will collaborate and share in the costs of
future trials of the drug, and lead global clinical development.
Regenxbio will participate in U.S. commercialization.
AbbVie will pay Regenxbio $370 million up front, with the
potential for Regenxbio to get up to $1.38 billion as the
partnership unfolds. The two companies will equally split U.S.
profits from the drug. AbbVie will pay Regenxbio royalties on
foreign sales.
Regenxbio will lead U.S. manufacturing, while AbbVie will take
the lead on foreign manufacturing.
A pivotal trial testing subretinal delivery of the drug is now
underway, the companies said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
September 13, 2021 06:56 ET (10:56 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024